• Swiss medical weekly · Oct 1999

    [High-risk PTCA assisted by the Hemopump 14F: the Geneva experience].

    • A Panos, A Kalangos, and P Urban.
    • Département de chirurgie, Hôpitaux Universitaires de Genève. aristotepanos@yahoo.com
    • Swiss Med Wkly. 1999 Oct 23; 129 (42): 1529-34.

    IntroductionThe hemopump is a transvalvular, catheter-mounted, left ventricular assist device, intended for surgical placement via the femoral artery (hemopump 21 Fr. outer diameter). This device has demonstrated its ability to unload the left ventricle, leading to myocardial protection and haemodynamic stabilisation in patients with cardiogenic shock and those undergoing high-risk coronary angioplasty (PTCA). Since 1994, a new hemopump system (14 Fr. in external diameter, flow rates of 1.5-2.2 l/min) has been developed for percutaneous insertion. The aim of this study is to describe the immediate and mid-term results obtained during Hemopump 14 Fr. assisted high-risk PTCA.PatientsBetween September, 1993 and July, 1996, 8 males and 5 female patients (mean age 68.5 +/- 8.6 years) underwent Hemopump 14 Fr. supported high-risk PTCA.ResultsMean duration of hemopump assistance was 108 +/- 62 min. Hemopump support on maximum speed led to an increase of cardiac index from 2.0 +/- 0.3 to 2.2 +/- 0.5 l/min (p = 0.04) and a decrease of pulmonary wedge pressure from 17 +/- 8 to 14 +/- 8 mm Hg (p = 0.004). LDH increased (463 +/- 305 to 558 +/- 237 u/l-p = 0.05) and the platelet count remained stable (192,840 +/- 60,904 to 190,230 +/- 56,492/mm3). Successful balloon angioplasty was performed in all patients. There was no hospital mortality. Three patients (23%) required blood transfusion. During follow-up, 1 patient (7.7%) developed femoral artery occlusion necessitating surgical repair, and 3 patients (23%) died from cardiac causes 3, 9 and 14 months after the procedure.ConclusionsThe 14 Fr. Hemopump device may constitute a useful percutaneous mode of haemodynamic support for patients undergoing high-risk PTCA. The haemolysis it causes is mild and not clinically significant, but the hemopump is associated with a significant rate of local vascular complications. Recent improvements in interventional techniques and hardware have decreased the necessity for circulatory assistance during elective PTCA, even for very ill patients. Nevertheless, indications such as cardiogenic shock, the "bridge" period prior to heart transplantation and video-assisted minimally invasive cardiac surgery, or haemodynamic support of the right ventricle are the new applications of the hemopump.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…